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Low back pain is widely recognized as one of the most prevalent pathologies in the developed world. In the United States, low
back pain is the most common health problem for adults under the age of 50, resulting in signiﬁcant societal and personal costs.
While the causes of low back pain are myriad, it has been signiﬁcantly associated with intervertebral disc (IVD) degeneration.
Current ﬁrst-line therapies for IVD degeneration such as physical therapy and spinal fusion address symptoms, but do not treat
the underlying degeneration. The use of tissue engineering to treat IVD degeneration provides an opportunity to correct the
pathological process. Novel techniques are currently being investigated and have shown mixed results. One major avenue of
investigation has been stem cell injections. Mesenchymal stem cells (MSCs) have shown promise in small animal models, but
results in larger vertebrates have been mixed.
1.Introduction
1.1. IVD and Low Back Pain. Intervertebral discs act as the
main joints of the spinal column, providing both stability
and ﬂexibility. In addition to facilitating bending, ﬂexion,
and torsion, they also help to transmit loads applied to the
spine. In the normal course of aging, the intervertebral disc
(IVD) and in particular the nucleus pulposus (NP) undergo
extensive morphological and cellular changes resulting in
hardening of the NP and a decrease in structural integrity,
disc height, and ﬂexibility of the IVD as a whole [1, 2].
Low back pain has been strongly associated with such
IVD degeneration [3, 4]. Numerous epidemiological studies
suggest that such back pain is widespread, frequently debil-
itating, and costly. Approximately 25% of American adults
reported low back pain occurring in the past 3 months.
This corresponds to over 54 million individuals [5]. Over a
lifetime, 70% to 80% of people will at some time experience
back pain [6]. Accordingly, in the United States, low back
pain is the ﬁfth most common reason for physician visits,
constituting approximately 2.3% of all appointments [5, 7].
Low back pain is frequently debilitating and as such is
responsible for signiﬁcant productivity losses. Accounting
for 149 million lost work days annually, back pain is the
second most common reason for sick leave, behind only
the common cold [8–10]. In a given year, 8% of the entire
working population will be disabled by back pain [11].
This results in signiﬁcant economic losses. As of 1997, it
w a sc a l c u l a t e dt h a tb a c kp a i nr e s u l t e di na na g g r e g a t ep r o -
ductivity loss of $28.17 billion in the US, although by some
estimates this ﬁgure may have been as high as $87.8 billion
[12, 13].
At least one recent study suggests that the incidence of
low back pain is increasing. Freburger et al. [14]f o u n da
6.3% increase—from 3.9% to 10.2%—in reported chronic
low back pain between 1992 and 2006. Given the costs and
discomfort associated with chronic low back pain, this
increase is concerning and underscores the import of ex-
ploring new treatment modalities.
In this paper, we discuss the potential of using MSCs to
treat IVD degeneration. We comment on current research
and conclude with recommendations for further study.
2. The IVD: Structureand Degeneration
2.1. Disc Morphology. The IVD is avascular and consists
mainly of a macromolecular extracellular matrix (ECM)
with a low-density population of cells that help to maintain
this ECM. Grossly, a normal IVD consists of a central2 Advances in Orthopedics
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Figure 1: Illustration of the main intervertebral disc structures and
vertebral column. CEP: cartilage endplate; AF: annulus ﬁbrosus;
NP: nucleus pulposus; VB: vertebral body; 1: spinal cord; 2: nerve
root; 3: apophyseal joint; 4: site of NP protrusion and nerve root
compression after IVD degeneration.
NP surrounded by the annulus ﬁbrosus (AF), all of which
is sandwiched between two cartilaginous endplates (EPs)
(Figure 1). The NP is relatively ﬂuid, composed primarily of
an ECM of collagen type II and proteoglycans. Functionally,
the collagen imparts tensile strength, while the proteoglycans
attract and bind water, providing resilience to compression.
Suspended throughout this ECM are chondrocyte-like cells.
Commonly, the consistency of the NP is described as “gel-
like.” In turn, the AF is composed of a series of concentric
r i n g s( l a m e l l a e )w h i c ha r ep r i m a r i l yc o l l a g e nI .T h eh i g h -
percentage of collagen makes the AF rigid, a property that
helps it to contain the more ﬂuid NP and contribute to the
integrity of the disc. Finally, the endplates separate the NP
and AF from the adjacent vertebral bone.
2.2. The Aging Disc. Histologic assessment has shown that
disc degeneration deﬁnitively begins in the early teenage
years [2, 15]. The discs of the lumbar spine bear a dispropor-
tionate amount of this wear [2]. Far from being static, the
disc ECM is subject to continuous synthesis and degradation
[16]. In IVD degeneration, the rate of matrix anabolism
slows, while matrix catabolism increases. This results in a
number of changes. Proteoglycan content in the NP drops
signiﬁcantly, and with it the ability of the ECM to attract and
retain water [16]. The number of chondrocytes in the ECM
decreases [15, 17]. Macroscopically, ﬁbrous tissue forms in
the NP, resulting in a loss of gel-like character and ultimately
leading to a dissolution of the distinction between NP and
AF [2]. Repeated mechanical loading [1, 18] and declining
nutrition [1, 19, 20] have been implicated as the two most
critical factors in degeneration.
Mechanical overloading of the IVD has been shown to
induce catabolic activity associated with degeneration [21].
It has also been suggested that the routine cycle of disc
deformation and recovery caused by normal activity could
eventually lead to fatigue failure of the disc [1].
Insuﬃcient nutrition is signiﬁcant in slowing matrix
anabolism. Because the IVD is avascular, it must receive
nutrients through diﬀusion. Blood vessels terminate at the
EP and nutrients then move down concentration gradients
across the plate and through the ECM to reach embedded
cells.ItiswellestablishedthattheEPsbecomelesspermeable
with age [20, 22], and Boos et al. [15] found histologic
evidence that a decrease in endplate blood vessels coincides
with an increase in disc ECM breakdown. Studies on disc
nutrition have suggested that glucose is the critical nutrient
for maintaining cell viability, with oxygen and pH acting
as secondary factors [19, 23]. When nutrition of the disc is
suﬃciently impaired, disruption of matrix synthesis and cell
death can occur [24, 25].
The other component in disc degeneration is breakdown
of the matrix. Matrix metalloproteinases (MMPs) and ag-
grecanases are two classes of enzymes involved in both
normal matrix turnover and degeneration. These enzymes
degrade the components of the ECM and have been found
at elevated levels in degenerated discs [26, 27].
3. Treatments: PresentandFuture
3.1. Current Treatments. Current treatments for disc degen-
eration fall into two categories. Conservative, nonsurgical
management entails analgesics, rehabilitation programs, and
lifestyle adjustments such as weight loss. Surgical interven-
tion involves spinal fusion and disc arthroplasty [28, 29].
While conservative management is the preferred treatment
method for most cases of IVD degeneration, patients not
beneﬁting from such management can realize beneﬁts from
surgical fusion [30]. Nevertheless, neither conservative nor
surgical management addresses the underlying process of
IVD degeneration, and for many patients neither is eﬀective
at relieving low back pain. Furthermore, fusion surgery has
signiﬁcant downsides. Beyond the loss of ﬂexibility between
fused vertebrae, fusion can also increase stress and strain
on adjacent discs and thus accelerate their degeneration,
necessitating further surgical intervention [31–33].
3.2. Emerging Treatments. A growing understanding of the
molecular changes associated with IVD degeneration has led
to a burgeoning exploration of various treatments designed
to directly address these changes [17]. In recent years,
therapies targeting several molecular and cellular aspects of
degeneration have been explored. One approach has been
the direct injection or stimulation through gene therapy of
a number of growth factors involved in regulating matrix
anabolism [34, 35]. This technique has shown promising
results in vitro and in vivo in small animal models [36–
40]. Another major avenue of investigation has been cell
therapy. The goal of cell therapy is to increase ECM synthesis
by repopulating the degenerate NP. To accomplish this, one
of several types of cells is injected directly into the NP
(Figure 2) .C e l lt y p e su t i l i z e dt h u sf a ri n c l u d eN Pc e l l s[ 41–
43], chondrocytes [44–46], and MSCs [44, 47–55], all of
which have exhibited potential for slowing and repairing
degeneration. In this paper, we focus on research regarding
MSCs.Advances in Orthopedics 3
Viral vector
encoding protein X
Harvesting of disc cells Harvesting of bone MSCs
Genetic
modiﬁcation
Seeding of
Transformed
cells
Cultivated
cells
Cell-seeded
scaﬀold
Transplantation of
autologous cells
Induction of
diﬀerentiation
Progenitor cells Diﬀerentiated cells
Injection of MSCs
Injection of
diﬀerentiated cells
Injection into IVD
expression of protein X
by transformed disc cells
(a) (b) (c)
scaﬀold
Figure 2: Diﬀerent treatments for IVD degeneration are illustrated. (a) Injecting a viral vector into the IVD causes expression of the coded
protein by the transformed disc cells. (b) Cells from the NP are harvested and then can be cultivated, genetically modiﬁed, or seeded into a
scaﬀold before being transplanted into the IVD. (c) Bone MSCs are harvested and injected into the IVD as MSCs or as diﬀerentiated cells.
4.Mesenchymal StemCells
4.1. Background and General Therapeutic Use. MSCs are
undiﬀerentiatedcellsfoundinseveraladulttissues.Themul-
tipotent nature of individual MSCs was ﬁrst demonstrated
by Pittenger et al. [56], and since then they have been found
to be pluripotent, giving rise to endoderm, ectoderm, and
mesoderm cells [57]. MSCs are well suited to therapeutic
application because they can be easily cultured and have
high ex vivo expansive potential [58]. They are also capable
of robust, persistent engraftment [57]. Furthermore, use of
MSCs avoids the ethical issues raised by embryonic stem cell
harvesting [59, 60]. MSCs have shown therapeutic promise
in a number of diverse applications including regenerating
infracted myocardium [61, 62], improving functional recov-
ery from ischemic stroke [63], and rescuing liver failure [64].
A number of mesenchymal tissues have been investigated
as MSC sources in adults (Table 1). Chief among these are
bone marrow [56], periosteum [65], synovial membrane
[66], and adipose tissue [67]. Two recent studies have
suggested that MSCs isolated from diﬀerent tissues exhibit
diﬀerent levels of expandability, chondrogenesis, osteogen-
esis, and adipogenesis, with synovium-derived MSCs being
generally superior [68, 69].
4.2. Use in IVD Degeneration: In Vivo Studies. An u m b e ro f
in vivo studies have examined the use of MSCs to slow the
process of IVD degeneration and regenerate the matrix. In
2003, Sakai et al. [51] conducted the ﬁrst study exploring
t h eu s eo fM S C st or e p a i rI V Dd e g e n e r a t i o nin vivo using
a rabbit model. Partial aspiration of the NP was used to
induce degeneration, and autologous MSCs embedded in
an Atelocollagen gel were then injected into discs. This
procedure was found to prevent histological and morpho-
logical disc degeneration when compared to a nontreated,
degeneration-induced control. Overall NP and AF structure,
cell volume, and matrix formation (in particular proteogly-
can content) were maintained up to 8 weeks after injection,
and implanted MSCs were found to have diﬀerentiated into
cells resembling original disc cells.
A number of other studies examining the use of MSCs in
small animals have demonstrated the ability of these cells to
survive, diﬀerentiate towards disc cells, and produce matrix
components including collagen II and proteoglycans. This
has been shown both with and without a number of cellular
scaﬀolds(Atelocollagengel,hyaluronangel,andPuraMatrix)
using autologous, allogenic, and xenogeneic (speciﬁcally,
human) MSCs, and with follow-up times ranging from
approximately one month to four months [47, 52–55]. Using
a rabbit model, Zhang et al. [55] found that transplanted
allogenic MSCs survived and increased proteoglycan and
collagen II synthesis in the NP. Wei et al. [53] used a rat
model to assess the ability of human MSCs to proliferate and
function within the IVD. After 6 weeks, MSCs demonstrated
survival and diﬀerentiation towards disc cells. Widespread
success using allogeneic and xenogeneic MSCs may reﬂect
the immune privilege of the IVD [70], as well as the
immunosuppressive capabilities of MSCs [71].
While small animal models have yielded universally pos-
itive results, the results of large animal studies have been
mixed. Henriksson et al. [48] injected human MSCs into4 Advances in Orthopedics
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porcine discs which were then harvested at up to 6 months.
At followup, MSCs were found to have survived and dif-
ferentiated toward disc cells, exhibiting matrix-producing
functionality. Similarly, Hiyama et al. [49]f o u n dM S C
injection into degeneration-induced canine discs to increase
proteoglycan content and eﬀectively mitigate degeneration.
While these results are encouraging, another recent large
animal study casts doubt on the potential of MSCs to
treat IVD degeneration clinically. Acosta et al. [44] injected
injured porcine discs with allogeneic MSCs. Discs were then
harvested at 3, 6, and 12 months. At all followups, no viable
MSCs or proteoglycan synthesis as observed. One reason
postulated for this includes the larger disc size and therefore
greater nutrient restriction present in the porcine model as
compared to small animal models. This larger disc size more
closely mimics the conditions in adult human IVDs, where
nutrients must travel up to 8mm from the terminal end of
the blood vessel to cells in the center of the disc [23].
5. FutureDirections
5.1. Critique of Current Studies. A notable criticism of cur-
rent studies involving in vivo implantation of MSCs is that
they do not accurately replicate the environment of the
human degenerate disc. This is true for several reasons.
Firstly, in all in vivo studies to date, MSCs have been
implanted either into unmodiﬁed, healthy, young discs [47,
52, 53, 55] or into discs where degeneration was simulated
by aspiration of the NP [44, 48, 49, 51] or annular injury
[50, 54]. While these techniques have been shown to induce
degeneration of the NP and AF as evidenced through MRI
[72], there is no evidence that they lead to the EP damage
typical in painfully degenerated IVDs, damage which likely
impairs nutrient diﬀusion. Lack of nutrients has been found
toimpairECMsynthesis[24,25]andpoorEPpermeabilityis
highly correlated with morphologic and biochemical degen-
eration [73]. The central role of nutrition in the eﬃcacy of
MSC treatment is further implicated in the results of Acosta
et al. [44], where it was hypothesized that the relatively
larger discs of minipigs compromised nutrient diﬀusion
and prevented the survival of implanted MSCs. Based on
current research, it is unclear whether repopulation without
nutritional supplementation will lead to eﬀective matrix
anabolism. In the future, development of a standardized in
vivo model that more accurately mimics disc degeneration
in humans would allow for more meaningful study of all
therapies targeting molecular and cellular components of
degeneration.
It is also worth noting that the histological and mor-
phological slowing and reversal of IVD degeneration may
not necessarily relieve low back pain. In fact, this was the
outcome of one clinical study using MSCs to repair cartilage
in osteoarthritis patients. Although biopsy and arthroscopic
observation demonstrated new cartilage growth, no signiﬁ-
cant clinical improvement was reported [74, 75]. At present
there exists no animal model for low back pain, making the
therapeutic beneﬁt of NP regeneration challenging to study
[76]. The clinical beneﬁt of restoring matrix integrity must
be further explored.
5.2. Obstacles in Translation to Clinical Use. Before stem cells
can be adequately and eﬃciently used in IVD degeneration,
it is imperative that the mechanisms of pathogenesis are
more clearly understood in order to answer many questions
that have been left from previous studies. The absence of an
animal model for low back pain involving IVD degeneration
makes it diﬃcult to truly study and assess the eﬀectiveness
of cell therapy. It has previously been studied that the
degenerating IVD creates a harsh environment by decreasing
nutrient supply from the EP, increasing the acidity of the
microenvironment and elevated inﬂammatory substances
[19, 74]. This hardly is the ideal environment required for
a successful graft, not only can cell survival be impaired but
the MSC’s diﬀerentiation maybe altered in anunknown way.
Another diﬃculty is establishing which patients are can-
didates for MSC therapy. A patient with a Thompson of 4-
5 most likely would not be a candidate due to the extreme
microenvironment [67]. It should be considered that 20–
50% of asymptomatic patients have radiological signs of
IVD degeneration raising the question of the timing of
the treatment [74]. Early treatment may perhaps be the
diﬀerence from symptom relief and failed therapy, regardless
of cell survival and proliferation. Two clinical trials show
diﬀerent results on symptomatic relief in patients with IVD
degeneration after undergoing stem-cell transplantation. A
Thompsonscoreof2-3mightbetheidealcandidateforMSC
therapy, but this remains to be studied.
Combination therapy, providing supportive matrix and
bioactive substances, may possibly be the best treatment
required,optimizingcellsurvival,proliferation,anddiﬀeren-
tiation [55, 74]. Several growth factors described in previous
studies have been implicated in IVD degeneration and ther-
apy. MSCs secreting transforming growth factor-beta (TGF-
β), Insulin-like growth factor-1 (IGF-1), and platelet-derived
growth factor (PDGF) have been found in cocultures with
NPcellsandhavebeenshowntobeaneﬀectivestimulatoron
matrix metabolism and cell proliferation during biological
repair of IVDs [13, 67]. Growth and diﬀerentiation factor-
5 has been shown to increase disc height and stimulate
proliferation and matrix synthesis in the NP and AF.
Furthermore, Henriksson et al. found endogenous stem cell
niches in the AF border to the ligament zone and the
perichondrium region [21]. The utilization of growth factors
maystimulateproliferationoftheseendogenousstemcells.It
isreasonabletoassumethatinjectionofnakedgrowthfactors
within the scaﬀold containing the MSCs at time of trans-
plantation may increase graft survival and cell proliferation
anddiﬀerentiationintoNP.Bringingintoquestionwhattype
of scaﬀold if any is the most adequate for transplantation.
Immunogenicity, architectural and mechanical properties
along with biocompatibility, biodegradability, and method
of graft delivery need to be considered when choosing the
scaﬀold [76]. Dosing studies will also need to be done in
order to determine the cell density and volume that will
need to be transplanted in order to obtain the desired eﬀect6 Advances in Orthopedics
while causing the least amount of side eﬀects. Moreover, to
be determined will be the need for subsequent treatments or
if one time treatment will suﬃce.
Given that the IVD is considered immunoprivileged, the
need to ﬁnd an autologous cell origin might not be necessary
[7,67].Althoughthisshouldbestudiedfurthertoascertainif
an immunosuppressive regimen will be needed and for how
long.
One last consideration is the ideal culture conditions of
the MSCs. First of all, in order to be used for clinical trials
it must be done in GMP grade conditions with xeno-free
reagents. Coculture of NP cells with MCS may be necessary
in order to enhance the biological and metabolic viability of
the cells [67]. It is important to consider that in vitro expan-
sion can lead to an accumulation of genetic and epigenetic
changes with an unknown eﬀect in vivo once transplanted.
The changes may lead to increased immunogenicity even
when autologous or malignant transformation.
6. Conclusion
It is evident that there are many questions left unanswered.
In order to move forward in ﬁnding an eﬀective therapeutic
option for IVD degeneration-associated back pain, they
will need to be studied further. One of the main obstacles
is creating an animal model that can adequately replicate
the microenvironment seen in IVD degeneration. Once
an animal model is established, more preclinical data will
be able to be collected in a directed way with adequate
conditions.
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